MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...

Painful diabetic neuropathy was associated with lower quality of life and higher rates of depression and anxiety than painless diabetic neuropathy.

Background Best current estimates of neuropathic pain (NeuP) prevalence come from studies using various screening detecting pain with probable neuropathic features; the proportion experiencing ...

Lexicon Pharmaceuticals, Inc. announced a conference call and webcast scheduled for March 3, 2025, at 8:00 a.m. ET to discuss topline results from the Phase 2b PROGRESS study of pilavapadin ...

Painful diabetic peripheral neuropathy (DPN ... The current study showed that DPN with concomitant neuropathic pain impacts QoL and mental health negatively and likewise for DPN without ...

MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

Neuropathic Pain Conditions - Covers diabetic neuropathy, postherpetic neuralgia (shingles-related pain), chemotherapy-induced peripheral neuropathy (CIPN), and complex regional pain syndrome ...